Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives

被引：19
|
作者：
Freitas Santos, Elton Jonh [1 ]
Carneiro Dias, Raimunda Sheyla [1 ]
de Brito Lima, Janielle Ferreira [1 ]
Salgado Filho, Natalino [2 ]
dos Santos, Alcione Miranda [2 ]
机构：
[1] Univ Fed Maranhao, Univ Hosp, Rua Barao de Itapary 227, BR-65020070 Sao Luis, Maranhao, Brazil
[2] Univ Fed Maranhao, Sao Luis, Maranhao, Brazil
来源：
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE | 2020年 / 13卷
关键词：
anemia; chronic kidney disease; erythropoietin; drug resistance; STIMULATING AGENT HYPORESPONSIVENESS; HEMODIALYSIS-PATIENTS; RENAL ANEMIA; INFLAMMATION; RESPONSIVENESS; POLYMORPHISM; CKD;
D O I：
10.2147/IJNRD.S239151
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Anemia is a frequent complication of chronic kidney disease, and its primary cause is erythropoietin deficiency. After diagnosis, treatment begins with administration of an erythropoiesis-stimulating agent (ESA). However, some patients present with resistance to ESA, which needs to be reversed, as it can increase the risk of death in patients with kidney disease. Therefore, we provide a discussion of the current literature regarding the factors that can modify the response to this class of drugs and the strategies that can be considered to optimize the benefits of treating anemia.
引用
收藏
页码：231 / 237
页数：7
相关论文
共 50 条
  • [1] Renal denervation in patients with chronic kidney disease: current evidence and future perspectives
    Schmieder, Roland E.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (05) : 1089 - 1096
  • [2] Frailty Screening in Chronic Kidney Disease: Current Perspectives
    Worthen, George
    Tennankore, Karthik
    [J]. INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2019, 12 : 229 - 239
  • [3] Erythropoietin resistance-secondary to watermelon stomach: a forgotten story in chronic kidney disease patients
    Sabanis, Nikolaos
    Paschou, Eleni
    [J]. PAN AFRICAN MEDICAL JOURNAL, 2023, 44
  • [4] Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease
    Bamgbola, Oluwatoyin F.
    [J]. KIDNEY INTERNATIONAL, 2011, 80 (05) : 464 - 474
  • [5] Renovascular Protective Effects of Erythropoietin in Patients with Chronic Kidney Disease
    Fujiwara, Nobuharu
    Nakamura, Tsukasa
    Sato, Eiichi
    Kawagoe, Yasuhiro
    Hikichi, Yutaka
    Ueda, Yoshihiko
    Node, Koichi
    [J]. INTERNAL MEDICINE, 2011, 50 (18) : 1929 - 1934
  • [6] Obstacles to Early Diagnosis and Treatment of Pruritus in Patients with Chronic Kidney Disease: Current Perspectives
    Jha, Chandra Mauli
    Dastoor, Hormaz Dara
    Gopalakrishnan, Natrajan
    Holt, Stephen Geoffrey
    [J]. INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2022, 15 : 335 - 352
  • [7] Anticoagulation in chronic kidney disease: current status and future perspectives
    Jones, Alfred
    Swan, Dawn
    Lisman, Ton
    Barnes, Geoffrey D.
    Thachil, Jecko
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (02) : 323 - 336
  • [8] Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5
    Rianthavorn, Pornpimol
    Boonyapapong, Pantipa
    [J]. PEDIATRIC NEPHROLOGY, 2013, 28 (08) : 1261 - 1266
  • [9] Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5
    Pornpimol Rianthavorn
    Pantipa Boonyapapong
    [J]. Pediatric Nephrology, 2013, 28 : 1261 - 1266
  • [10] Insulin resistance in patients with chronic kidney disease
    Toll, R
    Donate, T
    Mallafre, JM
    Ortiz, MA
    Arroyo, JA
    Pou, JM
    [J]. DIABETOLOGIA, 1996, 39 : 1129 - 1129
12345